Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,391 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Pill Clear all

Conditions: 16P11.2 Deletion Syndrome
Interventions: Arbaclofen, Placebo oral tablet; Drug
Lead sponsor: Clinical Research Associates, LLC; Other
Eligibility: 5 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas + 1 more

Conditions: Heart Failure
Interventions: Tolvaptan or Samsca, placebo or sugar pill; Drug
Lead sponsor: Cardiovascular Clinical Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 37
States / cities: Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 34 more

Conditions: Ocular Myasthenia Gravis
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Michael Benatar; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: New Haven, Connecticut • Miami, Florida • Kansas City, Kansas + 5 more

Conditions: Chronic Fatigue Syndrome, Cognitive Impairments
Interventions: Lisdexamfetamine Dimesylate, Placebo "30, 50 or 70 mg"; Drug
Lead sponsor: Rochester Center for Behavioral Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester Hills, Michigan

Conditions: Alcohol Use Disorder
Interventions: Semaglutide 3 MG [Rybelsus], Semaglutide 7 MG [Rybelsus], Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Huntington's Disease
Interventions: Tetrabenazine; Drug
Lead sponsor: William Ondo, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Transplantation
Interventions: tacrolimus, mycophenolate mofetil, Prednisone; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: Inotuzumab ozogamicin, Prednisone Pill, Daunorubicin, Vincristine, Cytarabine, Methotrexate, Pegaspargase; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 16 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Nashville, Tennessee • Charlottesville, Virginia • Richmond, Virginia + 1 more

Conditions: Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions: Placebo, Rifaximin; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 35 Years to 72 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Major Depressive Disorder
Interventions: Open-label Placebo; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Horizons International Peripheral Group; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Fairhope, Alabama • Houma, Louisiana • Lafayette, Louisiana

Conditions: Obesity
Interventions: Levonorgestrel 1.5mg by mouth once; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cannabis Dependence
Interventions: Aprepitant, Placebo, Manual-guided behavioral counseling; Drug · Behavioral
Lead sponsor: The Scripps Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Peripheral Arterial Disease
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 40 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Neutrophils.Hypersegmented &#X7C; Bld-Ser-Plas, STEMI - ST Elevation Myocardial Infarction
Interventions: Colchicine Pill; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 19 Years to 110 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Montelukast, Sugar pill; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Melanoma, Metastatic Melanoma
Interventions: Ipilimumab, Nivolumab, Troriluzole, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Concussion, Mild Traumatic Brain Injury
Interventions: Docosahexaenoic acid (DHA), Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 14 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Contraceptive Usage, Overweight or Obesity, Body Weight Changes, Appetitive Behavior, Eating Behavior
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Chronic Hepatitis C
Interventions: SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir), Ribavirin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 1,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 38
States / cities: Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more

Conditions: Healthy
Interventions: Memantine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Ecchymosis and Erythema Commonly Associated With Soft Tissue Filler Injections
Interventions: Multizyme Cellular Vitality Cyruta Plus SHEP; Dietary Supplement
Lead sponsor: DeNova Research; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancers - Throat
Interventions: Chemoradiation, Pamiparib, Hydroxyurea, Fluorouracil (5FU), Tislelizumab; Radiation · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

Efficacy of Prednisone In the Treatment of Ocular Myasthenia

Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome

Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)

A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)

Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Gulf War Digestive Health Study

Pilot Study of Open-label Placebo to Treat Major Depressive Disorder

Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

Effects of Obesity on Pharmacokinetics of the Levonorgestrel Emergency Contraceptive Pill

Treatment for Cannabis Withdrawal and Dependence

Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities

CLEAR SYNERGY Neutrophil Substudy

Moderate to Persistent Asthma in the Obese Subject

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

DHA For The Treatment of Pediatric Concussion Related to Sports Injury

Triple Therapy in T1DM

A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity

Study of Oral Treatments for Hepatitis C

Functional Neuroimaging of Alcoholism Vulnerability (PIT)

A Study of Nutritional Supplementation in Altering Ecchymosis, Erythema and Health Outcomes Associated With Aesthetic Procedures

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer